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Background
Antagonists of CXC chemokine receptor 4 (CXCR4), including AMD3100, induce periph-
eral mobilization of hematopoietic stem cells and have been approved for clinical use. 
We explored whether the CXCR4 antagonists affected the survival and proliferation of 
myeloid leukemia cells in vitro.
Methods
The effects of CXCR4 antagonists AMD3100 and T140 on the survival and proliferation 
of myeloid leukemia cell lines (U937, HL-60, MO7e, KG1a, and K562) as well as CD34
＋
cells obtained from patients with AML and CML were analyzed by flow cytometry by using 
annexin V and a colorimetric cell proliferation assay. 
Results
AMD3100, but not T140, stimulated the proliferation of leukemia cells in vitro in a 
dose-dependent manner for up to 5 days (∼2-fold increase at a concentration of 10
−5
M), which was not abrogated by pretreatment of the cells with pertussis toxin, but was 
attenuated by RNAi knockdown of CXCR7 transcripts. In contrast, AMD3100 induced 
a marked decrease in the cell numbers after 5-7 days. AMD3100, but not T140, induced 
phosphorylation of MAPK p44/p42. AMD3100 increased the number and size of leukemia 
cell colonies and reduced cell apoptosis during the first 5-7 days of incubation, but the 
phenomena were reversed during the later period of incubation.
Conclusion
The effects of CXCR4 antagonists on the proliferation of myeloid leukemia cells are not 
uniform. AMD3100, but not T140, exerts dual effects, initially enhancing and sub-
sequently inhibiting the survival and proliferation of the cells in vitro.
Key Words AMD3100, CXCR4, SDF-1, Myeloid leukemia, Cell proliferation, Apoptosis
*This study was supported by grants from 
the National Research Foundation of Korea 
(NRF-2009-0067256).
Correspondence to
Deog-Yeon Jo, M.D., Ph.D.
Division of Hematology/Oncology, 
Department of Internal Medicine, 
Chungnam National University Hospital, 
33 Munhwa-ro, Jung-gu, Daejeon 301-721, 
Korea
Tel: ＋82-42-280-7162
Fax: ＋82-42-257-5753
E-mail: deogyeon@cnu.ac.kr
Ⓒ2011 Korean Society of Hematology
INTRODUCTION
The chemokine stromal cell-derived factor-1 (SDF-1) in-
duces the migration and homing of hematopoietic stem cells 
(HSCs) and hematopoietic progenitor cells (HPCs) by signal-
ing via a G protein-coupled receptor, CXC chemokine re-
ceptor 4 (CXCR4) [1]. AML and CML cells also express 
CXCR4 [2,3] and respond to SDF-1, resulting in the traffick-
ing of these cells in the bone marrow (BM) microenviron-
ment [4]. SDF-1 alone has negligible effects on the pro-
liferation of both normal and malignant hematopoietic cells 
in vitro [5], but the SDF-1/CXCR4 axis has been shown 
to be involved in the development and progression of myeloid 
leukemia. For example, AML patients with high expression 
levels of CXCR4 in CD34
＋ cells had a significantly reduced 
survival rate and a higher probability of relapse than their 
counterparts [6]. Human AML cells were shown to con-
stitutively express SDF-1-dependent cell-surface elastase, 
which regulates their migration and proliferation [7]. A poly-
morphism in the SDF-1 gene has been correlated with the 
risk of distant tissue infiltration by AML cells [8], and func-
tional CXCR4-expressing microparticles and SDF-1 ex-
pression were found to be correlated with circulating AML 
cells [9]. Compared to Philadelphia chromosome (Ph)- neg-
ative CD34
＋CXCR4
＋ cells, Ph-positive CD34
＋CXCR4
＋ cells Korean J Hematol 2011;46:244-52.
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from CML patients were shown to migrate poorly [10]. These 
observations suggest that the modulation of the SDF-1/ 
CXCR4 axis may influence the biology of myeloid leukemia 
cells [11].
AMD3100, a small bicyclam molecule, was originally de-
veloped as a CXCR4 antagonist that blocked the entry of 
HIV into T cells [12]. AMD3100 inhibits the binding of 
SDF-1 to CXCR4 and induces peripheral mobilization of 
HSCs and HPCs [13]. AMD3100 induces the segregation 
of leukemic cells in the BM microenvironment [14, 15], 
resulting in enhanced chemosensitivity of the cells. On the 
basis of these observations, AMD3100 can be considered 
suitable for clinical application [11]. However, AMD3100 
has been shown to activate a G protein coupled to CXCR4, 
and thus acts as a partial CXCR4 agonist in vitro [16]. 
Furthermore, AMD3100 was shown to exert dual effects 
in bleomycin-induced lung inflammation in an animal model 
[17]. We have previously reported that AMD3100 enhanced 
the survival and proliferation of myeloma cells in short-term 
incubation in vitro [18]. In the present study, we explored 
whether AMD3100 and another CXCR4 antagonist, T140, 
affected the survival and proliferation of myeloid leukemia 
cells  in vitro.
MATERIALS AND METHODS
1. Cells and reagents
BM samples were obtained, with informed consent, from 
3 patients each with AML and CML at the time of diagnosis. 
CD34
＋ cells were purified from the BM by using the MACS 
system (Miltenyi Biotec, Auburn, CA). The human myeloid 
cell lines, U937, HL-60, K562, and KG1a, were purchased 
from the American Type Culture Collection (Manassas, VA). 
U937 cells were cultured in RPMI-1640 medium (Gibco-BRL 
Life Technologies, Grand Island, NY) supplemented with 
10% fetal bovine serum (FBS; Gibco-BRL Life Technologies). 
K562, KG1a, and HL-60 cells were grown in Isocove’s modi-
fied Dulbecco’s medium (IMDM; Gibco-BRL Life Technolo-
gies) supplemented with 10% FBS. MO7e cells were grown 
in IMDM supplemented with 10% FBS and 10 ng/mL gran-
ulocyte, macrophage colony-stimulating factor (R&D 
Systems, Minneapolis, MN). AMD3100 and pertussis toxin 
(PTX) were from Sigma Chemical Co. (St. Louis, MO). 
Another CXCR4 antagonist, the T140 peptide (H-Arg- 
Arg-Nal-Cys-Try-Arg-Lys-d Lys-Pro-Tyr-Arg-Cit-Cys-Arg- 
OH), was purchased from Peptron Inc. (Daejeon, Korea). 
Signal-blocking agents (wortmannin, LY294002, AG490, 
PD98059, rapamycin, and SB203580) were obtained from 
Calbiotech (Spring Valley, CA).
2. Flow cytometry
Cells were incubated with fluorescein isothiocyanate 
(FITC)-, phycoerythrin (PE)-, or allophycocyanin (APC)- 
conjugated monoclonal antibodies at 4
oC for 30 min and 
analyzed using a Coulter Elite flow cytometer (Coulter 
Electronics Ltd., Hialeah, FL) or a FACSCanto II flow cy-
tometer (BD Pharmingen, San Diego, CA). The monoclonal 
antibodies used were FITC-conjugated anti-CXCR4, PE-con-
jugated anti-CXCR4 (clone 12G5; BD Pharmingen), and 
APC-conjugated anti-CXCR7/RDC-1 (clone 11G8; R&D 
Systems). To detect cytoplasmic CXCR4 or CXCR7, the cells 
were permeabilized with a saponin-based reagent (BD 
Pharmingen) and labeled. To detect apoptosis, the cells were 
stained with FITC-conjugated annexin V (BD Pharmingen) 
and analyzed by flow cytometry. For cell cycle analysis, 
t h e  c e l l s  w e r e  s t a i n e d  w i t h  p r o p i d i u m  i o d i d e  ( P I ;  B D  
Pharmingen) and analyzed.
3. Migration assay
For the transmigration experiments, cells (2×10
5 cells/well) 
were loaded into the upper chamber of a 24-well Transwell 
plate containing a 5-μm microporous membrane (Corning- 
Costar, Cambridge, MA), and the cells were allowed to mi-
grate into the lower chamber containing 200 ng/mL SDF-1 
for 4 hr.
4. Cell proliferation assay
To examine whether AMD3100 and T140 affected the 
proliferation of leukemia cells, the 5 leukemia cells and pri-
mary CD34
＋ cells from 3 patients were incubated in se-
rum-free X-VIVO medium (BioWhittaker, Walkersville, 
MD) in the absence or presence of AMD3100 (10
−7 M to 
10
−5 M) or T140 (10
−7 M to 10
−5 M), for up to 72 hr 
and analyzed using a colorimetric assay kit (CCK-8 assay 
kit; Dojindo Laboratories, Tokyo, Japan) according to the 
manufacturer’s instructions. Briefly, 5×10
3 cells were in-
cubated in 96-well plates in serum-free X-VIVO medium. 
After incubation, 10 μL of CCK-8 solution, which was pro-
vided by the manufacturer, was added to each well. The 
optical density (OD) was measured 3 hr later by using a 
spectrophotometer (Molecular Devices Co., Sunnyvale, CA). 
The proliferation index and relative proliferation index rep-
resent the fold-increase in the OD compared with that of 
the matched control at each incubation time point and the 
fold-increase in the OD compared with that of the control 
at the beginning of the incubation, respectively.
5. Tumor cell colony assay 
Cells (8×10
3) were plated in triplicate in 35-mm tissue 
culture dishes (Corning Costar), containing 1 mL of an assay 
medium consisting of X-VIVO medium and 1.2% methyl-
cellulose (Stem Cell Technologies, Vancouver, BC, Canada). 
After 3-14 days of incubation at 37
oC in 5% CO2, the number 
of colonies, defined as cell clusters consisting of more than 
5 cells, was counted using an inverted microscope.
6. Western blot analysis
Western blot was used to detect the phosphorylation of 
signaling molecules. Cells were starved in serum-free me-
dium for 12 hr and then treated with AMD3100. The cells 
were collected by centrifugation, washed in phosphate-buf-
fered saline, and lysed using SDS sample buffer (187.5 mM 
Tris-HCl, pH 6.8, 6% [w/v] SDS, 100% glycerol, 150 mM Korean J Hematol 2011;46:244-52.
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Fig. 1. AMD3100 and T140 inhibit the SDF-1-induced chemotaxis of myeloid leukemia cells, and trigger the internalization of surface CXCR4. (A)
Four-hour transmigration of MO7e cells towards SDF-1 (200 ng/mL). AMD3100 and T140 were added at concentrations of 10
−5 M and 10
−6 M,
respectively. 
a)P＜0.05, compared to the control. (B) U937 cells were incubated with or without 10
−5 M AMD3100 and 10
−6 M T140, respectively,
for 3 hr and subsequently subjected to flow cytometry. 
DTT, and 0.03% [w/v] bromophenol blue). Equal amounts 
of protein from each sample were separated by electro-
phoresis on 10% SDS-polyacrylamide gels and transferred 
to polyvinylidene fluoride membranes (Amersham Life 
Science, Arlington Heights, IL). The membranes were 
blocked for 1 hr in TBS (Tris-buffered saline) containing 
5% (w/v) milk and 0.1% Tween 20, and then incubated 
with a primary mouse or rabbit monoclonal antibody (Cell 
Signaling Technology Inc., Danvers, MA) overnight at 4
oC. 
The blots were washed with TBS containing Tween 20, in-
cubated with anti-mouse or anti-rabbit secondary antibody 
for 2 hr, and developed using West-Zol Plus (iNtRON 
Biotechnology, Seoul, Korea). The following antibodies were 
used: anti-phospho-Akt polyclonal antibody (Ser473), an-
ti-Akt polyclonal antibody, anti-phospho-MAPK p44/p42 
polyclonal antibody (Thr202, Tyr204), anti-MAPK p44/42 
polyclonal antibody, anti-phospho-Stat3 polyclonal antibody 
(Tyr705), anti-Stat3 polyclonal antibody, anti-phospho- 
MAPK p38 polyclonal antibody (Thr180, Tyr182), and an-
ti-MAPK p38 polyclonal antibody (all from Cell Signaling 
Technology Inc.).
7. RNAi knockdown of CXCR4 and CXCR7
Cells were seeded onto 12-well plates (3×10
5 cells/well), 
incubated for 5-10 min at room temperature, and then trans-
fected with 5-25 nM CXCR4 siRNA or CXCR7 siRNA 
(Qiagen, Hilden, Germany) by using the HiperFect trans-
fection reagent (Qiagen), according to the manufacturer’s 
instructions. Cells were cultured in normal growth media 
for 24-72 hr after the transfection. Transfection efficiency 
of control siRNA was evaluated by fluorescence microscopy. 
Suppression of the cell surface levels of CXCR4 and CXCR7 
was analyzed by flow cytometry.
8. Statistical analyses
Results were expressed as the mean±standard deviation 
(SD) of at least 3 experiments. Data were analyzed using 
Student’s t test for paired samples. A P value of ＜0.05 was 
deemed to indicate statistical significance.
RESULTS
1. AMD3100 and T140 block the migration of leukemia cells 
in response to SDF-1
All the leukemia cells and primary CD34
＋ leukemia cells 
expressed CXCR4 on their cell surface (data not shown). 
SDF-1 induced the transmigration of leukemia cells into 
the lower chamber of a Transwell system, which was abol-
ished by treating the cells in the upper chamber with 
AMD3100 and T140 (Fig. 1A). Pretreating the cells in the 
upper chamber with PTX (200 ng/mL) for 2 hr also markedly 
inhibited the chemotaxis of the cells in response to SDF-1 
(data not shown). To further understand the activities of 
AMD3100 and T140, we examined whether these agents 
induce the internalization of cell surface CXCR4. Treatment 
of U937 cells with 10
−5 M AMD3100 or 10
−6 M T140 for 
3 hr in serum-free X-VIVO medium resulted in substantial 
internalization of surface CXCR4 (Fig. 1B).
2. AMD3100 stimulates myeloid leukemia cell proliferation 
SDF-1 alone did not affect the proliferation of the leukemia 
cells (data not shown). AMD3100, but not T140, increased 
the number of the leukemia cells, in a dose-dependent man-
ner (Fig. 2A, B). After 3-day incubation, 10
−5 M AMD3100 
increased the proliferation of MO7e, HL-60, KG1a, K562, 
and U937 cells by 1.3-, 1.2-, 1.5-, 1.6-, and 1.6-fold, re-
spectively, compared with the control (all P＜0.05). Similar Korean J Hematol 2011;46:244-52.
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Fig. 2. AMD3100 stimulates the proliferation of myeloid leukemia cells. Cells were incubated in the presence of AMD3100 (A) or T140 (B) for up 
to 72 hr. (C) Bone marrow CD34
＋ cells from 3 each patients with AML and CML were incubated in the presence of AMD3100 (10
−5 M) for 72 hr. 
(D) U937 cells were incubated with AMD3100 (10
−5 M). As indicated, the cells were pretreated with pertussis toxin (PTX) for 2 hr before the 
incubation. (E) U937 cells were incubated in X-VIVO medium with or without AMD3100 (10
−5 M) and subsequently subjected to cell cycle analysis.
(F) U937 cells were incubated in RPMI-1640 medium without serum in the presence or absence of AMD3100 (10
−5 M) for 72 hr, stained with 
annexin V and propidium iodide (PI), and subjected to flow cytometry. Representative flow cytometry profiles are shown in the left panel. In the right
panel, the percentages of the annexin V-positive apoptotic cells are presented 
a)P＜0.05, compared with the control.
results were observed for primary CD34
＋ cells (Fig. 2C). 
Pretreating the cells with PTX for 2 hr did not abrogate 
the increase in proliferation (Fig. 2D). Additionally, 
AMD3100 recruited more leukemia cells into the S phase 
(Fig. 2E).Korean J Hematol 2011;46:244-52.
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Fig. 3. AMD3100 induces the phosphorylation of SDF-1-linked signaling molecules. (A) MO7e cells were incubated with AMD3100 (10
−5 M) and
subsequently subjected to western blot analysis. Representative results of 3 experiments are shown. (B) U937 cells were treated with 10
−5 M 
AMD3100, 10 μM LY294002, 100 nM wortmannin, 50 μM PD98059, 10 μM AG490, 50 nM rapamycin, and 10 μM SB203580 for 3 days. 
3. AMD3100 inhibits the apoptosis of leukemia cells medi-
ated by serum deprivation
To investigate whether AMD3100 affected the apoptosis 
of leukemia cells, U937 cells were incubated in RPMI-1640 
medium in the absence FBS. After 72 hr, 16.9%±3.4% of 
the cells tested positive for annexin V. The addition of 
AMD3100 slightly reduced this to 9.5%±2.9% (P＜0.05; Fig. 
2F). Similar results were obtained for other leukemia cells 
(data not shown).
4. AMD3100 induces the phosphorylation of SDF-1-linked 
signaling molecules
We examined whether AMD3100 induced the phosphor-
ylation of Stat3, MAPK p38, Akt, and MAPK p44/p42, which 
are involved in SDF-1-mediated signaling, by using MO7e 
cells. Stat3, MAPK p38, Akt, and MAPK p44/p42 were con-
stitutively phosphorylated in MO7e cells at various levels. 
AMD3100 (up to 10
−5 M) induced modest phosphorylation 
of MAPK p44/p42, but not the others (Fig. 3A). Similar 
results were observed from other leukemia cells (data not 
shown). To further define the involvement of signaling path-
way(s) in the AMD3100-induced proliferation of leukemia 
cells, a proliferation assay was performed in the presence 
of various signal-blocking agents. U937 cells were incubated 
for 3 days with signal-blocking agents (LY294002, wortman-
nin, PD98059, AG490, rapamycin, and SB203580) in the 
presence or absence of AMD3100. The phosphatidyl in-
ositol-3 kinase inhibitor wortmannin, the MAPK p44/p42 
inhibitor PD98059, the MAPK P38 inhibitor SB203580, and 
the mTOR inhibitor rapamycin did not affect AMD3100-in-
duced or spontaneous proliferation of these cells (Fig. 3B). 
Similar results were observed with other leukemia cells (data 
not shown).
5. Extended-period culture
On the basis of a recent report that indicated that 
AMD3100 induced a marked inhibition of survival in leuke-
mia cells cultured for extended periods of up to 14 days 
[19], we further evaluated the effects of AMD3100 on the 
proliferation of leukemia cells in extended culture conditions 
( u p  t o  1 4  d a y s ) .  C o n t r o l  c e l l s ,  w h i c h  w e r e  i n c u b a t e d  i n  
serum-free medium alone, increased in total number for 
the first 5 days and decreased thereafter. A high concen-
tration of AMD3100 (10
−5 M) significantly enhanced the 
proliferation of leukemia cells during the first 5 days of 
incubation. In contrast, compared to the controls, AMD3100- 
treated cells exhibited a marked decrease in the cell number 
after 5-7 days of incubation (Fig. 4A). Addition of SDF-1 
at the beginning and at the middle of the incubation period 
did not affect the early increase or late decrease in the cell 
number (data not shown). In tumor cell colony assays using 
K562 cells, the number of colonies increased in the presence 
of AMD3100 during the early period of the assay, but mark-
edly decreased in the later period of the assay (Fig. 4B).
6. Knockdown of CXCR7, but not CXCR4, delays the pro-
liferation enhancement of AMD3100
Recently, AMD3100 was shown to bind to CXCR7 and 
to act as an allosteric agonist of this receptor [20], suggesting 
that CXCR7 may be involved in AMD3100-induced pro-
liferation enhancement. CXCR7/RDC-1 has been recently 
reported as another receptor for SDF-1 in many tumor cell 
lines [21]. Thus, we examined whether the cells expressed 
CXCR7/RDC-1 on their surface. CXCR7/RDC-1 was ex-
pressed at various levels in all the cells examined and was 
partially internalized after treatment with AMD3100, but 
not with T140 (Fig. 5). We next examined whether the 
knockdown of CXCR7 affected the aforementioned pro-
liferation enhancement. Transfection of CXCR4 siRNA into Korean J Hematol 2011;46:244-52.
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Fig. 4. Survival of leukemia cells in an extended period of culture. (A) HL-60 cells (a), K562 cells (b), KG1a cells (c), and U937 cells (d) were incubated
with AMD3100 (10
−7 M to 10
−5 M) for up to 14 days. Data are representative results of 3 or more independent experiments showing similar results.
(B) Effects of AMD3100 on the formation of tumor cell colonies were examined using K562 cells. Representative profiles of the colony assay are 
shown. 
U937 cells suppressed the expression of cell surface CXCR4, 
but it did not alter the proliferation enhancement. In contrast, 
the knockdown of CXCR7 significantly delayed the early 
proliferation enhancement (Fig. 6).
DISCUSSION
AMD3100, a specific antagonist of CXCR4, blocks the Korean J Hematol 2011;46:244-52.
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Fig. 5. Myeloid leukemia cells express CXCR7 on the cell surface, which is internalized by AMD3100. (A) Representative profiles of CXCR7 
expression on the cell surface. (B) U937 cells were incubated with 10
−5 M AMD3100 and 10
−5 M T140, respectively, for 3 hr and subsequently
subjected to flow cytometry.
Fig. 6. Knockdown of CXCR7, but not CXCR4, delays the 
proliferation enhancement induced by AMD3100. U937 cells 
were transfected with 25 nM CXCR4 siRNA or 5 nM CXCR7 siRNA 
and were further incubated in serum-free medium in the 
presence or absence of AMD3100 for up to 3 days. (A)
Representative profiles of the decrease in cell surface expression 
of CXCR4 and CXCR7 induced by siRNA. (B) Representative 
results of proliferation of the CXCR4 siRNA-transfected cells 
among 3 or more independent experiments showing similar 
results.  (C) Representative results of the proliferation of the 
CXCR7 siRNA-transfected cells among 3 or more independent 
experiments showing similar results.
binding of SDF-1 to CXCR4, resulting in the inhibition of 
the SDF-1-induced migration or proliferation of many cell 
types [19, 22]. However, few studies have addressed whether 
AMD3100 influences the survival or proliferation of myeloid 
leukemia cells [19, 22, 23]. Since myeloid leukemia cells 
produce SDF-1 [24], which possibly acts as an autocrine Korean J Hematol 2011;46:244-52.
Effects of AMD3100 on leukemia in vitro 251
growth factor, AMD3100 was expected to inhibit the pro-
liferation of these cells. Indeed, the CXCR4 antagonist 
4F-benzoyl-TN14003 has been shown to inhibit leukemia 
tumor growth [23]. We report here that AMD3100, but 
not T140, at a high concentration, for example 10
−5 M, 
stimulates the proliferation of myeloid leukemia cells during 
short-term incubation (up to 5 days) and protects cells from 
serum deprivation-induced apoptosis.
We found that AMD3100 induced the phosphorylation 
of SDF-1-linked signaling molecules in leukemia cells. 
However, the proliferation-enhancing effects of AMD3100 
in leukemia cells were not abrogated by pretreating the 
cells with PTX, a strong G protein-coupled receptor 
antagonist. Since CXCR4 is a PTX-sensitive G pro-
tein-coupled receptor [25], these results indicate that 
AMD3100 acts via pathways other than that mediated by 
CXCR4, to enhance cell proliferation. In our previous study, 
we have shown that AMD3100 enhanced the survival and 
proliferation of myeloma cells; the action of AMD3100 is 
not limited to a single cell type; and the proliferation en-
hancement induced by AMD3100 was markedly inhibited 
by PTX [18]. The reasons of the differences between myeloma 
and leukemia cells regarding the effects of PTX remain un-
clear and require further study.
Recently, CXCR7 has been identified as an alternative 
receptor for SDF-1 [26], and it has been shown to be involved 
in the endothelial adhesion and proliferation of several nor-
mal and malignant cell types, rather than their migration 
[27,28]. We have shown that AMD3100 induces the internal-
ization of not only CXCR4, but also CXCR7, indicating that 
AMD3100 interacts with CXCR7, consistent with a previous 
report demonstrating that AMD3100 binds to CXCR7 and 
acts as an allosteric agonist [20]. G protein-coupled receptors 
consist of 7-transmembrane domain receptors, including che-
mokine receptors, which signal through heterodimeric G 
proteins. It has been demonstrated that ligand binding to 
CXCR7 does not activate typical G-protein signaling path-
ways, but activates MAP kinases through beta-arrestin [29]. 
We found that AMD3100 phosphorylated MAPK p44/p42 
and that knockdown of CXCR7, but not CXCR4, delayed 
the initial proliferation enhancement. Altogether, it is sug-
gested that the early proliferation enhancement induced by 
AMD3100 is exerted via CXCR7, and not CXCR4.
AMD3100 was shown to inhibit the outgrowth of leukemia 
colony-forming units in vitro [22]. AMD3100 at a concen-
tration of 10
−5 M has also been shown to strongly impair 
the survival and stimulate the differentiation of leukemia 
cells, such as HL60 and U937, cultured for 7-9 days [19]. 
However, these results appear contradictory. In the present 
study, 10
−5 M AMD3100 enhanced the proliferation of the 
cells during the early course of incubation. After 5-7 days 
of culture, compared to the control cells, the number of 
cells treated with AMD3100 decreased more rapidly. Thus, 
the results from the 2 studies did not actually differ. It remains 
unclear whether the decrease in the cell number and increase 
in the cell apoptosis were induced directly by AMD3100, 
because higher cell density due to the increase in the cell 
number induced by AMD3100 in the early period of in-
cubation might deteriorate the culture condition. 
Conversely, the rapid cell death later in long-term incubation 
in vitro may be attributed to the AMD3100-mediated 
SDF-1/CXCR4 blockade. Normal hematopoietic cells pro-
duce SDF-1, which forms an autocrine/paracrine regulatory 
loop [30]. Because leukemia cells produce SDF-1 [24], it 
is possible that AMD3100 binding to CXCR4 blocks the 
autocrine loop of SDF-1. However, the mechanisms involved 
in AMD3100-induced cell death need to be further 
elucidated.
In summary, the effects of CXCR4 antagonists on the 
proliferation of myeloid leukemia cells are not uniform. 
AMD3100, but not T140, enhances the survival and pro-
liferation of myeloid leukemia cells during the early period 
of incubation in vitro. Although the observed proliferation 
enhancement was modest and only apparent in the early 
period of incubation and at a high AMD3100 concentration, 
caution must be exercised when considering the clinical 
application of this drug in patients with myeloid leukemia. 
Conversely, the inhibition of the proliferation and enhance-
ment of apoptosis during the later period of incubation sug-
gest a potential therapeutic use for AMD3100 in myeloid 
leukemia.
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